This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Edarbi

Arbor Pharmaceuticals, Inc.

Drug Names(s): TAK-491, azilsartan medoxomil, azilsartan kamedoxomil, Ipreziv (EU)

Description: TAK-491 is a prodrug that is hydrolyzed to the active moiety, TAK-536, which is a selective antagonist of the angiotensin II type 1 receptor subtype. Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of sympathetic nervous system, and smooth muscle cell growth.

Deal Structure: Takeda and Arbor
In September 2013, Takeda and Arbor announced that they have entered into a license, development and commercialization agreement. It will provide Arbor with exclusive rights to market and sell EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. market. Under the terms of the agreement, Arbor will have exclusive rights to promote and sell EDARBI and EDARBYCLOR in the United States. In return, Takeda will receive an upfront payment along with a series of future milestone and royalty payments based upon sales of the EDARBI family of products.

Partners: Takeda Pharmaceutical Company Ltd


Edarbi News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug